Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Byooviz™ (ranibizumab-nuna) – New biosimilar approval
On September 17, 2021, the FDA announced the approval of Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar to Genentech’s Lucentis (ranibizumab).
